Fortuna, Serena
 Distribuzione geografica
Continente #
EU - Europa 460
NA - Nord America 300
AS - Asia 87
OC - Oceania 2
AF - Africa 1
Totale 850
Nazione #
US - Stati Uniti d'America 295
DE - Germania 220
CN - Cina 53
SE - Svezia 51
PL - Polonia 49
IT - Italia 36
UA - Ucraina 36
FR - Francia 34
IN - India 13
GB - Regno Unito 12
IE - Irlanda 11
TR - Turchia 10
FI - Finlandia 6
MX - Messico 5
IR - Iran 4
KR - Corea 4
JP - Giappone 3
AU - Australia 2
BE - Belgio 2
NL - Olanda 2
CH - Svizzera 1
EG - Egitto 1
Totale 850
Città #
Chandler 72
Kraków 49
Jacksonville 24
Nürnberg 22
Chicago 20
San Mateo 19
Seattle 18
Nanjing 16
Ashburn 12
Dearborn 11
Dublin 11
Cattolica 10
Izmir 10
Woodbridge 9
Milan 8
Nanchang 8
Verona 8
Bremen 6
Hangzhou 6
Lawrence 6
New York 6
Redwood City 6
Boston 4
Houston 4
Leawood 4
Munich 4
Fremont 3
Gustavo Adolfo Madero 3
Kunming 3
Lancaster 3
Mountain View 3
Turin 3
University Park 3
Wilmington 3
Ann Arbor 2
Ardabil 2
Bari 2
Bengaluru 2
Bronxville 2
Brussels 2
Changsha 2
Hefei 2
Jinan 2
Shanghai 2
Tianjin 2
Amsterdam 1
Augusta 1
Berlin 1
Bordeaux 1
Burke 1
Busto Arsizio 1
Canberra 1
Cercola 1
Costa Mesa 1
El Segundo 1
Fontegreca 1
Fuzhou 1
Groningen 1
Guangzhou 1
Gurgaon 1
Hebei 1
Jiaxing 1
Kish 1
Los Angeles 1
Marseille 1
Melton South 1
Mexico 1
Monterotondo 1
Ningbo 1
Norwalk 1
Paris 1
Purley 1
Raleigh 1
Redmond 1
Sacramento 1
Secunderabad 1
Seoul 1
Shenyang 1
Taizhou 1
Tettnang 1
Zanjan 1
Zurich 1
Totale 456
Nome #
The role of small intestinal bacterial overgrowth in Parkinson's disease 176
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 169
Validation of a new HPLC-UV method for determination of the antibiotic linezolid in human plasma and in bronchoalveolar lavage 148
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 142
Variability of raltegravir plasma levels in the clinical setting 117
Validation of an UPLC-MS/MS Method for Quantitative Analysis of Raltegravir in Human Plasma Samples 102
Totale 854
Categoria #
all - tutte 2.071
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.071


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201929 0 0 0 0 0 0 0 0 0 0 17 12
2019/2020110 19 6 12 2 9 11 11 2 11 8 13 6
2020/202178 7 6 1 10 6 8 6 4 12 3 13 2
2021/202282 8 6 2 5 6 1 1 17 3 3 15 15
2022/2023168 20 30 22 28 6 20 3 16 13 5 5 0
2023/202450 5 16 0 6 4 8 3 0 1 5 2 0
Totale 854